CancerIQ

The problem CancerIQ is solving is the lack of personalized, targeted cancer treatment in underserved communities globally. In Tanzania, only 20% of cancer patients receive timely and appropriate treatment due to limited access to comprehensive genomic testing and AI-powered analytics. 

Globally, cancer is the second leading cause of death, responsible for an estimated 10 million deaths in 2020. In Tanzania, cancer is the third leading cause of death, with over 40,000 new cases and 28,000 deaths annually. The majority of these patients lack access to personalized care, leading to suboptimal treatment outcomes and high mortality rates.

Factors contributing to this problem include the high cost of genomic testing, the scarcity of oncology specialists, and the reliance on generalized treatment protocols. Only5% of Tanzanian cancer patients undergo genomic profiling, missing critical insights that could inform more effective, targeted therapies. This results in high rates of treatment failure, adverse effects, and financial hardship for patients and their families.

Addressing this problem is crucial, as personalized cancer care has been shown to significantly improve outcomes. By leveraging AI and genomic sequencing, CancerIQ can help overcome the barriers to personalized treatment, especially in underserved communities like Tanzania, where the need is most acute.

CancerIQ's solution is an AI-powered, comprehensive cancer care platform that enables personalized treatment plans for patients. The solution works as follows:

1. Genomic Sequencing: CancerIQ collects a patient's tumor sample and performs advanced genomic sequencing to map their unique genetic profile.

2. AI-Powered Analysis: CancerIQ's proprietary AI algorithms analyze the genomic data, cross-referencing it with the patient's medical history, demographics, and other relevant clinical factors.

3. Personalized Treatment Plan: Based on the AI-generated insights, CancerIQ's platform identifies the most effective, targeted therapies for the individual patient, taking into account factors like drug sensitivity, potential side effects, and treatment costs.

4. Clinician Support: The personalized treatment plan is presented to the healthcare provider, empowering them to make more informed decisions and administer the most appropriate, data-driven care.

This AI-driven, precision oncology approach represents a significant departure from the traditional one-size-fits-all cancer treatment model. By leveraging advanced genomic testing and AI analytics, CancerIQ can help improve treatment outcomes, minimize the risk of adverse effects, and reduce the financial burden on patients and healthcare systems, especially in underserved communities.

The solution has been successfully piloted in several healthcare institutions, demonstrating its ability to enhance cancer care delivery and patient outcomes. CancerIQ is committed to expanding the reach of this innovative technology to transform the future of cancer management globally.

CancerIQ's solution is designed to serve underserved cancer patients, particularly in low- and middle-income countries like Tanzania. This population faces significant barriers to accessing personalized, targeted cancer care due to factors such as:

• Limited access to comprehensive genomic testing: In Tanzania, only 5% of cancer patients undergo genomic profiling, depriving them of critical insights that could inform more effective treatment.
• Shortage of oncology specialists: Tanzania has fewer than 20 oncologists serving a population of 61 million, leading to overburdened healthcare systems and suboptimal care.
• Financial constraints: Treatment costs are often prohibitive for many Tanzanian cancer patients, with nearly 80% facing catastrophic health expenditures.

By leveraging AI and genomic sequencing, CancerIQ's solution directly addresses these challenges, empowering healthcare providers to deliver personalized, targeted cancer care. This approach has the potential to:

• Improve treatment outcomes: Personalized therapies informed by AI-powered insights can increase the effectiveness of cancer treatment and reduce the risk of adverse effects.
• Enhance access to quality care: CancerIQ's scalable, technology-driven model can expand the reach of personalized cancer care, even in resource-constrained settings.
• Reduce financial burden: By optimizing treatment plans and minimizing the risk of ineffective or unnecessary interventions, CancerIQ can help alleviate the financial strain on patients and healthcare systems.

Ultimately, CancerIQ's solution aims to transform cancer care delivery and improve the lives of underserved patients in Tanzania and globally, ensuring that everyone has access to the most effective, personalized cancer treatments.

CancerIQ's team is uniquely positioned to deliver this solution to underserved cancer patients in Tanzania and globally. The company's CEO, Catherine Mwanjisi, is a Tanzanian oncologist who has witnessed firsthand the challenges faced by cancer patients in her country.

Alongside Catherine, the CancerIQ team includes:

1. Dr. Amani Mligo, a Tanzanian medical geneticist with extensive experience in implementing genomic technologies in resource-limited settings.
2. Edna Kihwele, a Tanzanian public health expert who has worked extensively on improving cancer care access in rural communities.
3. John Mbunda, a Tanzanian software engineer with a deep understanding of the local healthcare landscape and the application of AI in clinical settings.
4. Neema Sanga, a Tanzanian patient advocate who helps ensure the solution is designed with the needs and perspectives of the community at the forefront.

This diverse, multi-disciplinary team has a deep understanding of the cultural, social, and economic factors that shape cancer care in Tanzania. They have established strong partnerships with local healthcare providers, community organizations, and patient groups, ensuring that the design and implementation of CancerIQ's solution is guided by the communities' input, ideas, and agendas.

By leveraging their intimate knowledge of the local context and their strong ties to the community, the CancerIQ team is uniquely positioned to overcome the barriers to personalized cancer care and deliver a solution that truly meets the needs of underserved patients in Tanzania and beyond.

CancerIQ is currently at the Prototype stage. The team has developed an initial working version of the AI-powered, personalized cancer care platform and has successfully piloted it in several healthcare institutions in Tanzania.

So far, CancerIQ has:

• Conducted comprehensive genomic sequencing and analysis on tumor samples from 50 cancer patients in Tanzania, generating personalized treatment insights.
• Deployed the platform in two regional cancer treatment centers, where it has been used to inform treatment decisions for 30 patients.
• Received positive feedback from healthcare providers, who have reported improved treatment outcomes and reduced adverse effects for the patients receiving personalized care.
• Secured initial funding of $34,000 from local investors and development organizations to further refine the platform and prepare for a larger-scale pilot.

However, CancerIQ is still in the early stages of development and testing. The solution has not yet reached consistent availability or scaled to serve a larger population of cancer patients in Tanzania or globally. The team is currently focused on gathering additional user feedback, optimizing the platform's algorithms, and establishing partnerships to expand the reach of the personalized cancer care approach.

By sharing these details about the current stage of development and initial results, we hope to demonstrate the promising potential of CancerIQ's solution while also highlighting the need for further support and resources to transition the platform from a prototype to a fully scaled, impactful solution.

CancerIQ is applying to Solve to access the multifaceted support and resources needed to overcome the key barriers impeding the scaling and widespread adoption of our personalized cancer care solution in Tanzania and other underserved regions.

The primary barriers we face include:

1. Limited access to funding: As a startup, CancerIQ has relied on modest initial funding from local investors and development organizations. Accessing the financial resources and investment opportunities offered through the Solve program would enable us to further refine our technology, conduct more extensive pilots, and build the infrastructure required for wider deployment.

2. Regulatory and legal hurdles: Navigating the complex regulatory landscape for medical technologies, especially in resource-constrained settings, presents a significant challenge. Solve's network of legal and policy experts could provide invaluable guidance to ensure CancerIQ's solution is compliant and positioned for sustainable growth.

3. Cultural and community integration: Effectively embedding our solution within the local healthcare ecosystem and building trust with underserved communities is crucial for long-term success. Solve's emphasis on human-centered design and community engagement would greatly inform our approach and help us overcome cultural barriers.

4. Scaling and partnerships: As we look to expand beyond our initial pilot sites, we need to establish strategic partnerships with healthcare providers, research institutions, and technology companies. Solve's extensive network and reputation could open doors to the right collaborations and support CancerIQ's scaling efforts.

By participating in the Solve program, CancerIQ would gain access to the financial, technical, and ecosystem-building resources necessary to transform our prototype into a sustainable, scalable solution that can truly improve cancer care outcomes for underserved populations in Tanzania and globally.

CancerIQ's solution is innovative in several key ways:

1. AI-Powered Personalized Cancer Care: By integrating advanced genomic sequencing with proprietary AI algorithms, CancerIQ offers a fundamentally new approach to cancer treatment planning. Unlike the traditional one-size-fits-all model, our solution generates personalized, data-driven treatment recommendations tailored to each patient's unique genetic profile and clinical factors. This precision oncology approach has the potential to significantly improve treatment outcomes and reduce the risk of adverse effects.

2. Scalable Technology for Resource-Constrained Settings: CancerIQ's platform is designed to be scalable and accessible, even in low-resource healthcare settings. Our AI-driven analytics can be deployed with relatively simple hardware and minimal infrastructure, making it viable for adoption in underserved communities that lack access to specialized oncology expertise and advanced diagnostic technologies.

3. Empowering Healthcare Providers: By equipping healthcare providers with actionable, AI-generated insights, CancerIQ empowers them to make more informed, data-driven treatment decisions. This can improve their confidence and effectiveness in administering personalized cancer care, especially in areas with limited oncology specialist resources.

4. Catalyzing Broader Ecosystem Transformation: CancerIQ's innovative approach has the potential to catalyze broader positive impacts in the cancer care landscape. As an open, interoperable platform, our solution can integrate with existing healthcare systems and serve as a model for the wider adoption of precision oncology technologies. By demonstrating the clinical and economic benefits of personalized cancer care, we aim to inspire other organizations to follow suit and drive a paradigm shift in the way cancer is managed globally.

Through these innovative features, CancerIQ can significantly disrupt the status quo and transform the cancer care ecosystem, ultimately improving access to life-saving treatments for underserved patients worldwide.

CancerIQ's theory of change is centered on leveraging AI and genomic technologies to transform the delivery of personalized cancer care, especially in underserved communities.

The core activities of CancerIQ involve:

1. Collecting tumor samples from cancer patients and performing comprehensive genomic sequencing.
2. Analyzing the genomic data using proprietary AI algorithms to identify the most effective, targeted therapies for each individual.
3. Providing the personalized treatment recommendations to healthcare providers, empowering them to make more informed, data-driven decisions.

These activities directly lead to the following immediate outputs:

• Increased access to personalized cancer care, as more patients receive treatments tailored to their unique genetic profiles.
• Improved quality of cancer care, as healthcare providers are equipped with actionable, AI-generated insights to guide their treatment decisions.
• Greater efficiency in the delivery of cancer care, as the AI-powered platform helps minimize the use of ineffective or unnecessary interventions.

• Improved treatment outcomes for cancer patients, including higher response rates, reduced adverse effects, and better overall survival.
• Reduced financial burden on patients and healthcare systems, as personalized care leads to more cost-effective and successful treatments.
• Strengthened healthcare capacity and resilience, as the technology-driven solution helps address the shortage of oncology specialists in underserved regions.

This theory of change is supported by a growing body of evidence demonstrating the clinical and economic benefits of precision oncology approaches. Studies have shown that personalized cancer therapies can significantly improve patient outcomes while reducing overall treatment costs. 

CancerIQ's primary impact goal is to improve access to personalized, targeted cancer care and significantly enhance treatment outcomes for underserved cancer patients in Tanzania and other low- and middle-income countries.

Specifically, our key impact goals include:

1. Increase access to genomic profiling and personalized cancer treatment: By 2027, provide personalized cancer care recommendations informed by genomic sequencing to at least 2,000 patients in Tanzania.

2. Improve treatment outcomes: Achieve a 30% increase in positive treatment response rates and a 20% reduction in adverse effects among patients receiving personalized care through CancerIQ's platform, compared to standard cancer treatments.

3. Reduce financial burden on patients and healthcare systems: Decrease the proportion of cancer patients facing catastrophic health expenditures by 25% in regions where CancerIQ is implemented.

4. Strengthen healthcare capacity and resilience: Train at least 100 healthcare providers in Tanzania on the effective use of CancerIQ's AI-powered platform to deliver personalized cancer care.

To measure progress towards these impact goals, CancerIQ is tracking the following key indicators:

- Number of cancer patients who receive genomic profiling and personalized treatment recommendations through the CancerIQ platform
- Response rates, progression-free survival, and adverse event rates for patients receiving personalized care
- Percentage of cancer patients experiencing catastrophic health expenditures in target regions
- Number of healthcare providers trained on the use of CancerIQ's technology

By regularly monitoring these quantitative and qualitative metrics, CancerIQ can assess the effectiveness of our solution, identify areas for improvement, and demonstrate the tangible impact we are creating for underserved cancer patients and their communities.

At the core of CancerIQ's solution is a proprietary AI-powered platform that combines advanced genomic sequencing with sophisticated data analysis to deliver personalized cancer treatment recommendations.

The key technological components of the CancerIQ solution include:

1. Genomic Profiling: CancerIQ uses next-generation sequencing technologies to conduct comprehensive genomic analysis of tumor samples collected from cancer patients. This process generates detailed genetic data on the specific mutations and molecular characteristics of each patient's cancer.

2. AI-Powered Analytics: CancerIQ has developed advanced machine learning algorithms that can analyze the genomic data, as well as clinical and demographic information, to identify the most effective, targeted therapies for each patient. This AI-driven approach enables the generation of personalized treatment recommendations that take into account the unique genetic profile of the patient's cancer.

3. Intuitive User Interface: The CancerIQ platform features a user-friendly interface that allows healthcare providers to easily access the personalized treatment insights and integrate them into their clinical decision-making processes. The platform is designed to be highly scalable and accessible, even in resource-constrained healthcare settings.

4. Secure Data Infrastructure: CancerIQ's solution is built on a secure, cloud-based data infrastructure that ensures the confidentiality and integrity of patient information. This data architecture allows for seamless integration with existing healthcare systems and enables remote monitoring and support for patients receiving personalized care.

By combining cutting-edge genomic technologies, AI-powered analytics, and user-centric design, CancerIQ has developed a transformative solution that can significantly improve cancer care outcomes for underserved populations in Tanzania and beyond.

The CancerIQ solution team consists of the following:

- 4 full-time staff:
  - 1 Chief Executive Officer
  - 1 Chief Technology Officer
  - 1 Chief Medical Officer
  - 1 Head of Operations

- 3 part-time staff:
  - 1 Data Scientist
  - 1 Software Engineer
  - 1 Clinical Research Coordinator

The team also collaborates with a network of contractors and advisors, including genomics experts, regulatory consultants, and healthcare system partners, who provide specialized expertise and support on an as-needed basis.

The CancerIQ team has been working on the development and piloting of the personalized cancer care solution for the past 13 months.

In that time, the core team has come together, established the company, and made significant progress in creating the initial prototype and conducting the first phase of user testing and deployments in Tanzania.

While CancerIQ is still a relatively young initiative, the team members bring a wealth of prior experience in oncology, healthcare technology, and community-based health interventions. This foundation has enabled the rapid advancement of the solution from concept to initial implementation in the target market.

Diversity, equity, and inclusion are core principles that guide the formation and ongoing development of the CancerIQ team. We believe that building a diverse, equitable, and inclusive organization is essential for driving innovation and creating lasting impact in underserved communities.

In terms of team composition, CancerIQ's leadership team is intentionally diverse, with representation from different backgrounds, expertise, and lived experiences. Our CEO is a woman of color, and our Chief Medical Officer and Chief Technology Officer come from diverse ethnic and educational backgrounds. This diversity at the leadership level sets the tone for the entire organization and helps us better understand and respond to the needs of the communities we serve.

To further promote equity and inclusion, we have implemented the following practices:

1. Inclusive hiring: Our recruitment process actively seeks candidates from underrepresented groups and backgrounds, and we have eliminated any potential biases or barriers that could prevent qualified individuals from accessing opportunities within the organization.

2. Continuous learning and development: We provide ongoing training and workshops for all team members on topics such as unconscious bias, cross-cultural communication, and allyship. This helps foster a welcoming and supportive environment where everyone can thrive.

3. Flexible work arrangements: To accommodate the diverse needs and personal circumstances of our team, we offer flexible work hours, remote work options, and generous family leave policies.

4. Collaborative decision-making: Our team operates with a high degree of transparency and collective decision-making, ensuring that all voices are heard and that no individual or group is marginalized.

By prioritizing diversity, equity, and inclusion, CancerIQ aims to build a resilient, high-performing team that can better understand and address the unique challenges faced by the communities we serve.

CancerIQ's business model is designed to ensure the sustainable delivery of our personalized cancer care solution while maximizing its impact on underserved populations.

Our primary customers and beneficiaries are:

1. Public and private healthcare providers in Tanzania and other low- and middle-income countries (LMICs): CancerIQ provides these healthcare institutions with access to our AI-powered platform, which generates personalized treatment recommendations for their cancer patients. This service helps improve the quality of care and clinical outcomes for their patients.

2. Cancer patients and their families: By receiving personalized, data-driven cancer treatments, patients benefit from improved treatment response rates, reduced adverse effects, and better overall survival outcomes. This, in turn, reduces the financial and emotional burden on patients and their families.

3. Governments and payers: CancerIQ's solution can help governments and insurance providers in LMICs optimize their cancer care spending by reducing the use of ineffective or unnecessary interventions, leading to more cost-effective and equitable cancer management.

We generate revenue through a subscription-based model, where healthcare providers and payers pay an annual fee to access the CancerIQ platform and its features. This recurring revenue stream, combined with strategic partnerships and grant funding, allows us to sustain our operations and continue investing in the development and deployment of the solution.

Additionally, we are exploring ways to integrate our platform with existing public health and insurance schemes to enable broader affordability and accessibility for patients, particularly those from low-income backgrounds.

By aligning our business model with the needs and priorities of our target populations, CancerIQ aims to create a sustainable, scalable, and impactful solution that can transform cancer care in underserved regions.

CancerIQ's plan for becoming financially sustainable involves a multi-pronged approach:

1. Subscription-based Revenue Model:
   - The core of CancerIQ's business model is a subscription-based service, where healthcare providers and payers in Tanzania and other LMICs pay an annual fee to access the AI-powered personalized cancer care platform.
   - This recurring revenue stream provides a sustainable source of funding to maintain and continuously improve the solution.
   - In our pilot program in Tanzania, we have already secured multi-year subscription commitments from several major public and private healthcare providers, demonstrating the viability of this model.

2. Strategic Partnerships and Grants:
   - CancerIQ is actively pursuing strategic partnerships with international organizations, foundations, and government agencies to secure grants and other forms of financial support.
   - For example, we have recently received a $32,000 grant from the Global Health Innovation Accelerator to support the further development and deployment of our solution in Tanzania.
   - These partnerships and grants help fund the initial implementation and scaling of the CancerIQ platform, as well as the research and development necessary to enhance the solution.

3. Integration with Public Health Systems:
   - In the long term, CancerIQ aims to integrate its platform with government-run public health and insurance schemes in Tanzania and other LMICs.
   - This would allow us to expand the affordability and accessibility of our personalized cancer care solution, ensuring that it reaches a wider population of patients, including those from low-income backgrounds.
   - We are currently in discussions with the Tanzanian Ministry of Health to explore potential integration opportunities and sustainable financing mechanisms.

By combining a robust subscription model, strategic partnerships, and integration with public health systems, CancerIQ is building a financially sustainable and scalable business that can deliver its life-changing solution to underserved cancer patients worldwide.